/
111, Inc. ADR is a healthcare and pharmaceutical platform focused on connecting consumers, pharmacies, and healthcare providers in China. The company operates through online retail pharmacy, Internet hospital, and B2B drug distribution businesses, supporting both individual customers and corporate partners with access to medical and wellness products, consultation services, and prescription-related offerings. Its platform combines digital and offline channels to serve the broader healthcare supply chain, with activities centered on pharmaceutical sales, patient services, and pharmacy network enablement. 111, Inc. ADR plays a role in China’s evolving digital healthcare market by helping streamline access to medicines and related services across consumer and business segments. Founded in 2010 and headquartered in Shanghai, the company is positioned as a technology-enabled participant in healthcare distribution and services.
$3.63
$0.16 (-4.22%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-0.02% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 12.8% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 54% versus the prior year, cash generation momentum has weakened.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
¥11.39B
▼ -12.8% YoY
Net Income (TTM)
-¥42M
▼ -8.4% YoY
Op. Margin
-0.20%
ROIC
-0.34%
▼ -0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-¥90M
▼ -53.7% YoY
Op. Cash Flow (TTM)
-¥90M
▼ -50.2% YoY
Net Debt
-¥324M
Net Cash Position
Cash & Equiv.
¥561M
3Y CAGR: -2.4%
Continue Research
111, Inc. ADR (YI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, 111, Inc. ADR scores 34/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
111, Inc. ADR scores 34 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -0.2% operating margin and a -0.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh YI's valuation and scores 34/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.